Age-related hypogonadism is a gradual decline in testosterone production that occurs as men get older, reaching levels low enough to cause noticeable symptoms. Unlike hypogonadism caused by injury or genetic conditions, this form develops slowly over decades as the hormone-producing system loses efficiency at multiple points. It’s also called late-onset hypogonadism, and roughly 39% of men aged 45 and older have testosterone levels that fall below the standard clinical threshold.
How Testosterone Production Slows With Age
Testosterone production depends on a chain of signals between three parts of the body: a region of the brain called the hypothalamus, the pituitary gland just below it, and the testes. The hypothalamus releases a signaling hormone that tells the pituitary to produce another hormone (LH), which then tells the testes to make testosterone. Testosterone levels, in turn, signal back to the brain to regulate the whole cycle. Aging doesn’t break one link in this chain. It weakens all of them simultaneously.
In healthy older men, the hypothalamus sends about 50% less signaling output to the pituitary compared to younger men. The pituitary’s signals become smaller and less effective. And the testes themselves lose responsiveness: by age 80, the ability of the testes to produce testosterone in response to pituitary signals declines by an estimated 75% compared to age 20. On top of that, the brain becomes roughly twice as sensitive to testosterone’s “slow down” signal, meaning even modest testosterone levels can cause the brain to further reduce its output. The result is a system that progressively dials itself down from every direction.
Testosterone levels typically remain within normal range until around age 60 for most men, though the decline begins as early as 30. For every 10-year increase in age, the risk of clinically low testosterone rises by about 17%.
Symptoms That Define the Condition
Many symptoms overlap with normal aging, which makes age-related hypogonadism tricky to identify. A large study published in the New England Journal of Medicine found that only three symptoms reliably cluster with genuinely low testosterone levels: fewer morning erections, reduced sexual desire, and erectile dysfunction. These sexual symptoms form the core of the clinical picture.
Other commonly reported symptoms include fatigue, loss of energy, sadness, difficulty with vigorous physical activity, and reduced ability to walk long distances or bend and kneel easily. While these physical and psychological symptoms are real and often improve with treatment, they weren’t as tightly linked to low testosterone on their own. Depression and fatigue, for instance, have many possible causes. The sexual symptoms are the most specific signal that testosterone is the underlying issue.
How It’s Diagnosed
Diagnosis requires both symptoms and a confirmed blood test. The American Urological Association uses a total testosterone level below 300 ng/dL as the primary cutoff, a figure broadly supported by other medical societies (which use thresholds ranging from 230 to 350 ng/dL depending on the organization). The New England Journal of Medicine study identified a stricter syndromic definition: at least three sexual symptoms combined with a total testosterone below 320 ng/dL.
Testosterone levels fluctuate throughout the day, peaking in the morning, so blood draws are typically done before 10 a.m. A single low reading isn’t enough. Guidelines call for a repeat measurement on a separate day to confirm the result. Major medical organizations, including the Endocrine Society, recommend against routine screening in men who don’t have symptoms.
The Role of Weight and Metabolic Health
Body fat and testosterone have a strong inverse relationship. Fat tissue contains an enzyme that converts testosterone into estrogen, and this creates a self-reinforcing cycle: lower testosterone promotes fat storage, and more fat tissue drives testosterone levels down further. Inflammatory signals from fat cells also suppress the brain’s hormone-signaling chain, compounding the problem.
Men with metabolic syndrome or type 2 diabetes have an especially high prevalence of low testosterone. The relationship runs both directions. Low testosterone is an independent risk factor for developing metabolic syndrome and type 2 diabetes, and men with those conditions are significantly more likely to become hypogonadal over time. One Finnish study found that men with metabolic syndrome at baseline had increased risk of developing hypogonadism over an 11-year follow-up. Conversely, men with higher testosterone levels had a 42% lower risk of developing type 2 diabetes.
This means that for many men, age-related hypogonadism isn’t purely about age. Excess weight and poor metabolic health accelerate the decline and can push testosterone below symptomatic thresholds years earlier than aging alone would.
Lifestyle Changes That Can Help
Before considering medication, weight loss, exercise, and better sleep are considered first-line interventions. Each targets a different piece of the problem. Losing excess body fat reduces the conversion of testosterone to estrogen and lowers the inflammatory signals that suppress hormone production. Sleep is when most testosterone is produced: men with lower testosterone levels tend to have worse sleep efficiency, more nighttime awakenings, and less time in the deep sleep stages that drive hormone release. Addressing sleep apnea, if present, is particularly important since low overnight oxygen levels are directly associated with lower testosterone.
These aren’t minor tweaks. For overweight men with borderline testosterone, lifestyle changes alone can sometimes bring levels back above the symptomatic threshold without any medical treatment.
Testosterone Replacement Therapy
When lifestyle changes aren’t enough, testosterone replacement therapy (TRT) is the standard medical treatment. The most common options are:
- Skin gels: Applied daily to clean, dry skin. These are the most widely used form in the U.S. and provide steady testosterone levels. You need to avoid skin-to-skin contact with others while the gel is wet to prevent transfer.
- Injections: Given into a muscle every one to two weeks for standard formulations, or every 10 weeks for long-acting versions (which require a clinic visit).
- Oral tablets: Taken twice daily, a newer and less common option.
After starting TRT, follow-up visits assess whether symptoms are improving, whether the testosterone level has reached the target range, and whether any side effects have appeared. One of the most common side effects is an increase in red blood cell production, which requires periodic blood monitoring.
Safety of Treatment
The two biggest historical concerns about TRT have been cardiovascular risk and prostate cancer. A recent systematic review and meta-analysis of 41 randomized controlled trials found no statistically significant increase in major cardiovascular events, prostate cancer events, or clinically significant prostate cancer among men receiving testosterone therapy. This supports short- to mid-term safety, though long-term data spanning decades are still limited.
Prostate monitoring is still part of routine follow-up. Guidelines recommend a urology consultation if, during the first year of treatment, prostate-specific antigen (PSA) rises by more than 1.4 ng/mL above baseline, exceeds 4.0 ng/mL total, or if a physical exam detects any abnormality. After the first year, prostate screening follows standard age-based recommendations.